BMY
$56.64
Bristol-Myers Squibb
($.69)
(1.20%)
BMY
Earnings Whisper ®
N/A
2nd Quarter June 2017
Consensus:  $0.74
Revenue:  $4.96 Bil
Thursday
Jul 27
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when BMY reports earnings?
Beat
Meet
Miss

Where is BMY's stock price going from here?
Up
Flat
Down
Stock chart of BMY
Analysts
Summary of analysts' recommendations for BMY
Score
Grade
Pivots
Resistance
$58.37
$57.87
$57.25

$56.75

Support
$56.13
$55.63
$55.01
Tweet
Growth
Description
Bristol-Myers Squibb Company is a global leader in the research and development of innovative lifesaving and life-enhancing treatments for heart disease; high blood pressure; stroke; diabetes; cancer; HIV/AIDS and other infectious diseases; depression, schizophrenia and other mental disorders; pain; and other conditions.
Peers
Regeneron PharmaceuticalsVertex PharmaceuticalsCelgeneEli LillyBioMarin PharmaceuticalJohnson & JohnsonZoetisEndo International plcPfizerMerck & Co.